{'fraction_non_alphanumeric': 0.019940179461615155, 'fraction_numerical': 0.0029910269192422734, 'mean_word_length': 5.944636678200692, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P1-29 Using international evidence to develop a conceptual framework of facilitators and barriers of chlamydia screening service in community pharmacies

Introduction Community pharmacies have recently become more involved in providing chlamydia testing and treatment CT&T. We have reviewed published evidence and developed a conceptual framework regarding facilitators of and barriers to access and provision of chlamydia testing and treatment in community pharmacies. Methods Electronic databases were searched using the keywords and grey literature was solicited from experts. Studies selected were imported to NVIVO8 and thematic analysis was performed to identify key facilitators and barriers to acceptability/success of CT&T community pharmacy service. The emerging themes were categorised to develop a conceptual framework. Results 17 papers and reports were included. The framework developed suggests barriers and facilitators operate at three conceptual levels; i) Service delivery, ii) Young people's decision to access service; and iii) Policy stakeholders' strategies. Some factors operate at more than one level. Key service user factors identified were convenience of access (location, no need for appointment and extended opening hours for pharmacies), pharmacy visits free of social stigma, within-pharmacy facilities for example, counselling area and toilet, level of privacy and confidentiality and self-perceived risk of chlamydia. Identified barriers at provider level were, insufficient promotion of service, staff workload and untrained staff. Policy stakeholders' strategies of implementing services in deprived areas, health professionals' relationship with pharmacy staff and incentives were considered key to the success. Conclusion Chlamydia screening in community pharmacies is broadly acceptable to both service users and providers. However if screening is to succeed, policy makers must accommodate the facilitators and barriers identified by young people and pharmacy staff.